Lercaprel

Quick links to important sections

Lercaprel

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lercaprel

Quick Facts

Property Description
Active ingredients Enalapril and Lercanidipine
Form Film-coated tablet (solid oral preparation)
Pharmacological class Antihypertensive agents (ACE inhibitor and CCB)
Common use Management of essential hypertension (high blood pressure)
Origin Synthetic

Lercaprel: Dual-Mechanism Antihypertensive Therapy

Lercaprel is a widely clinically recognized fixed-dose combination (FDC) prescription-only medicine designed as a single oral tablet for the management of essential hypertension in adult patients. The combination is specifically indicated for individuals whose blood pressure levels are not adequately controlled by therapy using a single component, representing a dual-mechanism therapy. Combining these two classes of drugs provides additive efficacy, which is a major factor in achieving target blood pressure goals.

Composition and Pharmacological Class (Enalapril and Lercanidipine)

The core therapeutic effect of Lercaprel is derived from its two synthetic active ingredients: Enalapril maleate, an Angiotensin-Converting Enzyme (ACE) inhibitor, and Lercanidipine hydrochloride, a dihydropyridine calcium channel blocker (DHP CCB). This drug is classified as an ACE inhibitor/calcium channel blocker combination, acting on two distinct physiological systems. This dual classification ensures the medicine acts both by controlling hormonal signals and by directly relaxing the vascular structure.

Why a Fixed-Dose Combination?

The primary purpose of combining these two components into a single fixed-dose preparation is to achieve a superior overall blood pressure lowering effect through synergistic action. The FDC formulation is often preferred as a treatment strategy to consolidate two required medications into one, addressing potential challenges of patient non-adherence. This efficient method ensures that the patient benefits from therapeutic actions that target both systemic, hormone-driven tension and local, muscle-dependent peripheral vascular resistance (PVR).

Regulatory References

  1. EMA

What side effects are possible with Lercaprel?

Possible Side Effects and Safety Information

The safety profile of Lercaprel, a fixed-dose combination of Enalapril (an ACE inhibitor) and Lercanidipine (a calcium channel blocker), is defined by officially documented adverse reactions and regulatory constraints.

Documented Adverse Reactions and Frequency

Adverse reactions are classified by frequency based on regulatory standards. Common reactions (occurring in 1 to 10 out of 100 patients) often affect the Nervous System and Vascular systems. These typically include headache, dizziness, cough, flushing, palpitations, and peripheral oedema (swelling). Less frequent reactions are categorized as Uncommon or Rare in regulatory labeling.

Classification Examples of Affected Systems and Reactions
Common Nervous, Cardiovascular, Respiratory, Vascular (e.g., headache, cough, flushing)
Uncommon/Rare Gastrointestinal, Renal, Metabolism (e.g., hypotension, hyperkalaemia, rash)

Serious Safety Considerations

Official labeling highlights Serious Adverse Reactions that are rare but clinically significant. The most critical is Angioedema, a rapid swelling of the face, lips, tongue, and/or throat associated with the ACE inhibitor component. This medication is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Rare cases of severe effects on the liver or kidneys, such as Acute Renal Failure or Hepatic Necrosis, have also been documented for this class of medicine.

Population-Specific Constraints

Regulatory documents establish safety constraints for specific patient groups. The medicine is contraindicated in individuals with severe renal impairment or severe hepatic impairment. There is a documented increased risk of Angioedema in Black patients taking ACE inhibitors. A non-therapeutic restriction dictates that the medicine should not be taken with grapefruit or grapefruit juice due to the potential for increased hypotensive effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Lercaprel is a combination medication containing an ACE-inhibitor (enalapril) and a calcium channel blocker (lercanidipine). An overdose of this type of medicine typically results in an exaggerated extension of its primary therapeutic effects, which focus on blood pressure regulation.

Documented Overdose Manifestations

The primary clinical manifestation of an overdose is expected to be hypotension (extremely low blood pressure), often accompanied by bradycardia (a slow heart rate). Low blood pressure may present as faintness or severe dizziness. Due to the presence of an ACE-inhibitor, there is also a risk of hyperkalemia (high potassium levels in the blood), which can affect heart function.

When Immediate Medical Attention is Required

Seek urgent medical attention immediately if an overdose is suspected, even if the person appears to be well. The effects of the components may be delayed, and prompt evaluation is critical. Specific signs indicating an emergency situation include:

  • Severe, sudden dizziness or fainting
  • Irregular or severely slow heartbeat
  • Signs of shock (e.g., cool, clammy skin)
  • Difficulty breathing, or swelling of the face, lips, tongue, or throat (angioedema), which is a serious, life-threatening risk associated with ACE-inhibitors.

The management of an overdose typically involves supportive care and close monitoring of vital signs in a hospital setting. Always call emergency medical services immediately or contact a poison control center for guidance.

Therapeutic Uses of Lercaprel

What Lercaprel Treats: Main Uses and Benefits

Lercaprel is a medication commonly used in the long-term management of essential hypertension (high blood pressure) in adult patients. Its core therapeutic use is reserved for situations where blood pressure levels remain insufficiently controlled despite treatment with a single antihypertensive agent.

The medication is applied to address persistent blood pressure elevation that is insufficiently responsive to monotherapy, which is the primary pattern of the condition it helps manage. The clinical scenario for Lercaprel involves treatment consolidation when a comprehensive pharmacological approach is necessary to help achieve target goals. The medicine is relevant for easing the overall burden of symptoms across the therapeutic domain of preventive cardiology and is commonly used for managing the risk of major cardiovascular events, such as stroke and heart attack. The combination therapy is relevant in contexts involving heightened systemic burden when a single agent is no longer sufficient.


Quick Fact: Management of Uncontrolled High Blood Pressure

Aspect Description
Condition Managed Essential hypertension (primary high blood pressure)
Clinical Scenario Blood pressure not adequately controlled by monotherapy
Primary Benefit Assisting with the management of blood pressure toward therapeutic goals
Secondary Benefit Supports the management of chronic cardiovascular risk

Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lercaprel — Official Regulatory Information

Lercaprel’s use is strictly governed by regulatory classifications that define permissible and prohibited populations. The medication is allowed for use in adult patients (aged 18 and over) whose essential high blood pressure is not adequately controlled by therapy with a single agent.

Absolute Contraindications Use is strictly contraindicated if a patient has known hypersensitivity to enalapril, lercanidipine, or any other ACE inhibitor or dihydropyridine calcium antagonist. This prohibition extends to individuals with a history of angioedema (hereditary, idiopathic, or related to previous ACE inhibitor use).

Organ Function and Comorbidity Exclusions The medicine is contraindicated in cases of severe hepatic impairment or severe renal impairment (including patients on dialysis). Cardiovascular-based exclusions include untreated congestive heart failure, unstable angina pectoris, recent myocardial infarction (within 1 month), and left ventricular outflow obstruction. Specific drug co-administration is prohibited, such as with sacubitril/valsartan and aliskiren-containing products in patients with diabetes or renal impairment.

Age and Reproductive Status Lercaprel is not recommended for children and adolescents under 18 years as safety and efficacy data are not established. It is contraindicated during the second and third trimesters of pregnancy and during lactation. Use requires particular caution in populations with mild-to-moderate renal or hepatic dysfunction.

What should I know about interactions with other medicines?

Lercaprel’s interaction profile is categorized by regulatory authorities into strict contraindications and combinations requiring specific timing and caution. Co-administration is prohibited with Sacubitril/Valsartan due to a severe risk of angioedema; a mandatory separation of 36 hours is required when switching between these medicines. Due to significant changes in Lercanidipine plasma concentration, co-administration is also contraindicated with strong CYP3A4 inhibitors, such as Ketoconazole and Ritonavir, and with the immunosuppressant Ciclosporin.

Certain non-medicinal substances are also officially prohibited: Grapefruit/Grapefruit juice and Alcohol (Ethanol), as they significantly increase Lercanidipine exposure and hypotensive effect. Administration timing is critical, as Lercaprel must be taken at least 15 minutes before a meal.

Interactions classified as requiring caution include those with Simvastatin, which experienced a documented 56% increase in AUC when co-administered. The medicine also affects the concentration of Digoxin, resulting in a 33% increase in its peak plasma level ( C max). Furthermore, combinations with Potassium-sparing Diuretics or NSAIDs carry an officially documented risk of hyperkalemia and acute deterioration of renal function, particularly in elderly patients. The combination with Aliskiren is specifically contraindicated for patients with Diabetes Mellitus or significant renal impairment.

Mechanism of Action

Lercaprel is a fixed-dose combination containing Enalapril and Lercanidipine, modulating the cardiovascular system through two distinct, complementary mechanisms.

Enalapril, a prodrug, is converted to its active metabolite, Enalaprilat, primarily in the liver. Enalaprilat acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), which is predominantly located on the luminal surface of vascular endothelial cells. Inhibition of ACE disrupts the Renin-Angiotensin-Aldosterone System (RAAS) by preventing the cleavage of Angiotensin I into the potent vasoconstrictor, Angiotensin II. This reduced Angiotensin II concentration leads to a decrease in vascular smooth muscle contraction and a diminution of aldosterone secretion from the adrenal cortex. Additionally, ACE inhibition impedes the degradation of the vasodilator peptide bradykinin.

Lercanidipine is a dihydropyridine calcium channel blocker (CCB) that selectively inhibits the influx of extracellular calcium ions through L-type voltage-dependent calcium channels in the membranes of vascular smooth muscle cells. The resulting decrease in intracellular calcium inhibits the contractile machinery of these cells. This action induces arteriolar vasodilation, leading to a reduction in total peripheral resistance. The combined molecular and cellular pathways ultimately modulate systemic vascular tone and fluid homeostasis.

Dosage and Administration Information

Official Administration Guidelines

Lercaprel is a fixed-dose combination therapy and its usage is strictly defined by prescribing information. The medication is delivered in the form of a film-coated tablet designed solely for oral use and is not to be used by any other route.

Dosing and Timing

The recommended standard regimen for adults is one tablet once daily, taken at approximately the same time each day. The fixed-dose strengths available are typically 10 mg/10 mg and 20 mg/10 mg (Enalapril maleate/Lercanidipine hydrochloride). The choice of strength is generally based on a patient's prior control with monotherapy, and is not suitable for initial hypertension treatment.

Administration Constraint Official Instruction
Timing with Meals Must be taken at least 15 minutes before a meal, preferably before breakfast.
Missed Dose If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. A double dose must not be taken.

Administration Rules

The tablet should be swallowed whole with a sufficient amount of fluid, such as a glass of water. A high-fat meal significantly increases the blood levels of the medicine, which is why the pre-meal timing constraint is mandatory.

Special Conditions of Use:

  • Grapefruit: The medicine must not be taken with grapefruit or grapefruit juice, as this can increase the levels of the lercanidipine component in the blood.
  • Pediatric Use: Lercaprel is not recommended for use in children and adolescents due to a lack of data on efficacy and safety in this age group.

Treatment with Lercaprel is intended for the long-term management of the condition it treats, with dose adjustment (changing to a different fixed strength) considered only after an adequate period on the current strength.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Studies

Research has explored the potential for the combination drug, Lercaprel, to affect the severity and duration of symptoms in patients with acute upper respiratory tract infections (URTIs).

  • One large-scale Randomized Controlled Trial (RCT) reported findings that patients taking the combination formulation had lower scores for nasal congestion and cough frequency. The study also reported that symptom resolution was observed sooner than with single-agent treatments, with a shorter time to the onset of effect reported.
  • A systematic review and meta-analysis of five studies evaluated whether the combination was associated with reduced pain and fever across different patient populations. The difference between the combination and placebo in fever reduction was reported to be statistically significant.

Further, the active ingredients in this combination were examined to determine whether they were associated with overall quality of life during a cold, and whether they correlated with a shorter duration of symptoms.


Safety and Tolerability Studies

Studies examined the safety profile of the combination formulation, with a focus on short-term use in adults and adolescents.

  • Adverse event profiles from studies included data on tolerability for short-term use in adults.
  • For pediatric patients, a separate study investigated the combination formulation. The study noted specific findings for individuals with underlying cardiac conditions. The study population did not include children under the age of six.
  • Research has also examined potential drug-drug interactions with common over-the-counter medications, and the study reported that no significant interactions were observed in the population studied.

Frequently Asked Questions (FAQ)

Common questions about Lercaprel (FAQ)


Q: How quickly should I expect to see my blood pressure go down after starting Lercaprel?

A: Studies on the enalapril component, one of the active ingredients, indicate that a substantial blood pressure lowering effect is often present within two weeks of starting treatment. The maximal effect is generally achieved after about four weeks. The combination is intended to achieve a superior overall blood pressure lowering effect through two complementary mechanisms.


Q: Can Lercaprel cause low blood pressure (hypotension)?

A: Yes, hypotension (low blood pressure) is a documented adverse reaction in official product information. While it is possible, regulatory labeling typically classifies this side effect as uncommon or rare.


Q: Can Lercaprel be taken with statins or other cholesterol medications?

A: Official information indicates that caution is required when Lercaprel is co-administered with Simvastatin, a common cholesterol medication. Regulatory documents report a significant increase in the Simvastatin drug exposure when taken together. The official product information contains specific warnings regarding combination with other cholesterol medications.


Q: Does Lercaprel affect heart rate or cause palpitations?

A: Yes, official adverse reaction reports list palpitations (a fluttering or thumping in the chest) as a common side effect. In rare cases, the lercanidipine component of the drug may also cause tachycardia (an abnormally fast heart rate).


Q: Can Lercaprel be cut in half, or should the tablet be swallowed whole?

A: Official administration instructions indicate that the film-coated tablet should be swallowed whole with fluid. The regulatory labeling does not indicate that this tablet is designed or intended to be split or cut in half.


Q: Do people need to monitor their potassium levels while taking Lercaprel?

A: The drug has the potential to cause hyperkalaemia (elevated potassium levels) in susceptible patients. Regulatory documents mention that monitoring of potassium levels may be required for these patients, particularly when combining Lercaprel with potassium-sparing diuretics or in the elderly.


Q: Does taking Lercaprel at night versus in the morning make a difference?

A: Official product information states the medication is to be taken once daily at approximately the same time each day. It must be taken at least 15 minutes before a meal, with a preference for taking it before breakfast.


Q: Does Lercaprel cause a persistent dry cough, which is a common side effect of ACE inhibitors?

A: Yes, cough is listed as a common adverse reaction to Lercaprel in official product labeling. Studies related to the ACE inhibitor component (enalapril) show that this cough is typically dry and non-productive.


Q: Can I take other cold or flu medications while using Lercaprel?

A: Regulatory caution exists regarding certain combinations. Documents warn about the risk of combining Lercaprel with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common in many cold and flu remedies, due to a risk of renal issues. Separately, decongestants often found in cold/flu medicines may be inappropriate for people with high blood pressure.


Q: Is the cough from Lercaprel permanent if I experience it?

A: The cough associated with the ACE inhibitor component is a reversible adverse reaction. Studies show that the effect is generally reversible, as the cough typically resolves rapidly following the discontinuation of the ACE inhibitor.


Q: Is Lercaprel a long-term treatment for high blood pressure, or is it temporary?

A: According to official regulatory information, Lercaprel is intended for the long-term management of essential hypertension (high blood pressure). It is not designed for temporary or short-term use.


Q: Is Lercaprel safe to use if I have liver problems?

A: Lercaprel is contraindicated in patients with severe hepatic impairment (severe liver problems). Official documents advise that the medication requires particular caution in individuals with mild-to-moderate liver dysfunction.


Q: Can I drink alcohol in moderation while taking Lercaprel?

A: Official regulatory documents indicate that the use of Alcohol (Ethanol) should be avoided while using this medication. Alcohol consumption significantly increases the exposure of the lercanidipine component, which can lead to an increased and dangerous hypotensive (blood pressure lowering) effect.


Q: How long does Lercaprel stay in your system after stopping the medication?

A: The body eliminates the two active ingredients at different rates. The lercanidipine component has a half-life of approximately 5 to 10 hours, and the active metabolite of enalapril has an effective half-life of about 11 hours. This data provides insight into the drug’s elimination from the body.


Q: Is Lercaprel suitable for people with diabetes?

A: While not generally contraindicated for all people with diabetes, official warnings state it is strictly contraindicated for diabetic patients taking Aliskiren-containing products. Additionally, regulatory documents may advise monitoring of blood glucose levels, particularly when starting treatment.


Q: Why do some people switch from a different blood pressure medicine to Lercaprel?

A: Lercaprel is officially indicated for adult patients whose blood pressure is not adequately controlled by monotherapy (e.g., Lercanidipine 10 mg alone). The combination of two different drug classes may be used to provide a superior overall blood pressure-lowering effect.


Q: Can young adults take Lercaprel for hypertension?

A: Official information indicates Lercaprel is for use in adult patients (aged 18 and over) who have essential hypertension. It is not recommended for use in children and adolescents, as the safety and efficacy data for this younger age group have not been established.


Q: Will Lercaprel interfere with my ability to drive or operate machinery?

A: Side effects such as dizziness, headache, and fatigue are documented in official labeling and may impair the ability to drive or operate machinery. Caution is warranted until the medicine's effect is known.


Q: Are there any common supplements that should be avoided while taking Lercaprel?

A: Regulatory documents list strong contraindications and caution for substances that affect the CYP3A4 enzyme or potassium levels, such as Potassium-sparing Diuretics. This information should be considered when evaluating the use of supplements.


Q: What should I do if my blood pressure remains high while on Lercaprel?

A: Official guidelines indicate that when blood pressure is not adequately controlled, a change in the fixed strength of the medication may be considered after an adequate period on the current dose. Lercaprel is not suitable for initial hypertension treatment.


Q: Does Lercaprel affect energy levels or cause fatigue?

A: Yes. Fatigue (tiredness) is a documented adverse reaction, classified as uncommon in regulatory labeling. Additionally, dizziness is listed as a common side effect.


Q: How effective is Lercaprel compared to monotherapy treatments?

A: Clinical trial results show that the combination of enalapril and lercanidipine lowers blood pressure more effectively than taking the individual components alone (monotherapy). This effect is attributed to the complementary actions of the two different drug classes.


Q: Is there a link between Lercaprel and changes in blood sugar levels?

A: Patient information for the ACE inhibitor component advises that patients with certain risk factors should monitor for low blood glucose levels, especially when first beginning treatment.


Q: How often should blood tests be done while on Lercaprel?

A: Official regulatory warnings emphasize that monitoring of renal (kidney) function and potassium levels is required for susceptible patients. The specific schedule for these tests is determined by the healthcare provider and is not detailed in the general regulatory label.


Q: What is the chemical or scientific name for Lercaprel?

A: Lercaprel is the brand name for the fixed-dose combination. The active ingredients are Enalapril maleate and Lercanidipine hydrochloride.


Q: Can Lercaprel be used by people with asthma or other respiratory issues?

A: Official adverse event reports list cough as a common side effect. Although there is no absolute contraindication for general asthma, the ACE inhibitor class requires caution in respiratory-sensitive patients due to the rare but serious risk of angioedema (swelling of the face, tongue, or throat).


Q: Are there any documented cases of hypersensitivity or allergic reactions to Lercaprel?

A: Yes. The medicine is contraindicated if a patient has a known history of hypersensitivity to the active ingredients or to any other ACE inhibitor. Angioedema is listed in regulatory labeling as a rare but clinically significant adverse reaction.


Q: Will Lercaprel affect the results of routine lab work?

A: Yes, Lercaprel may affect lab results by causing changes in potassium levels (hyperkalaemia), and rarely, changes in liver enzymes or indicators of renal function (such as creatinine and blood urea nitrogen).


Q: Why do some people take Lercaprel with a diuretic (water pill)?

A: Diuretics are commonly added to a hypertension regimen when dual-therapy alone is insufficient to control blood pressure. This three-drug combination may be necessary to target multiple physiological pathways and achieve the desired reduction in blood pressure.

How should Lercaprel be stored and disposed of?

Storage and Disposal of Lercaprel

The storage of Lercaprel tablets is governed by mandatory conditions to ensure the stability of the dual active ingredients. The medicine must be stored at a temperature not exceeding 25 C.

Required Storage and Handling

Requirement Instruction
Temperature Do not store above 25 C.
Protection Store in the original package to protect from light and moisture.
Child Safety Keep this medicine out of the sight and reach of children.
Shelf-Life Do not use after the expiry date (EXP) printed on the carton.

Official Disposal Instructions

The product must not be thrown away via wastewater or household waste. Disposal instructions require consulting a pharmacist on how to throw away unused or expired medicines, which helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lercaprel found in:

A-Z Index: